Codexis Inc. (CDXS) Stock Price Down 1.6%
Codexis Inc. (NASDAQ:CDXS) was down 1.6% during mid-day trading on Thursday . The company traded as low as $4.22 and last traded at $4.33, with a volume of 90,738 shares changing hands. The stock had previously closed at $4.40.
A number of equities research analysts have recently issued reports on CDXS shares. Zacks Investment Research lowered Codexis from a “hold” rating to a “sell” rating in a research report on Monday, July 18th. HC Wainwright reiterated a “buy” rating on shares of Codexis in a research report on Tuesday, May 10th.
The firm’s market capitalization is $176.25 million. The firm has a 50-day moving average of $4.16 and a 200 day moving average of $3.81.
Codexis (NASDAQ:CDXS) last announced its quarterly earnings data on Tuesday, August 9th. The company reported $0.12 EPS for the quarter, beating the Zacks’ consensus estimate of $0.03 by $0.09. The firm earned $16 million during the quarter, compared to analyst estimates of $15.10 million. Codexis’s revenue for the quarter was up 166.7% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.14) EPS. Equities research analysts anticipate that Codexis Inc. will post ($0.21) EPS for the current fiscal year.
In other news, major shareholder Ventures Fund Vii L.P. Vivo sold 80,000 shares of Codexis stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $4.22, for a total transaction of $337,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.